Stocks · News reference
Canaccord Genuity analyst Richard Close maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $37 to $43.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-15 AccNo: 0001793229-26-000077 Size: 160 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
The WTC Health Program is a limited federal health care program established under the James Zadroga 9/11 Health and Compensation Act of 2010 (Extended in 2015). It provides nationwide medical monitoring and treatment to
Barclays analyst Glen Santangelo maintains Claritev (NYSE:CTEV) with a Overweight and raises the price target from $28 to $40.
Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX:MRAI) has expanded its relationship with Claritev to bring comprehensive pre- and